Xin'an, L., Jianying, Z., Lizhi, N., Fei, Y., Xiaohua, W., Jibing, C., . . . Kecheng, X. (2014). P0079 alleviating the pain of unresectable hepatic tumours by percutaneous cryoablation: Experience in 73 patients. European Journal of Cancer, 50(Suppl. 4), E31.
To review the changes in the severity of pain before and after percutaneous cryoablation of hepatic tumors
Patients with large tumors (major diameter P5 cm) underwent transarterial chemoembolization (TACE) first and then cryoablation. Cryosurgeries of hepatic tumors were performed on all 73 patients using an argon gas-based cryosurgical unit with two freeze/thaw cycles. Maximal freezing time was 15 minutes followed by natural thawing for 5 minutes x 2. A margin of at least 1 cm of normal hepatic tissue was frozen circumferentially around the tumor.
Six patients had an immediate relief of severe pain, 11 had relief within 15 days of cryosurgery (these were of the 17 patients with pain prior to the procedure), 39 were always pain-free, and 17 had new pain with the procedure but total relief within 15 days.
The pain-relieving effect of cryosurgery was immediate for some patients but all eventually experienced the complete disappearance of pain for at least eight weeks. Pain relief was delayed for some patients due to edema, which resulted from the treatment.
Cryoablation is a potential pain-relieving treatment for primary and metastatic tumors of the liver, but more studies are needed before this can be recommended as a modality to manage pain. Evidence to support long-term results beyond eight weeks also is lacking.
Xie, J., Chen, L.H., Ning, Z.Y., Zhang, C.Y., Chen, H., Chen, Z., . . . Zhu, X.Y. (2017). Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: A single-blind, randomized, controlled trial. Chinese Journal of Cancer, 36, 6-016-0176-1.
To investigate the effects of transcutaneous electrical acupoint stimulation (TEAS) on chemotherapy-induced nausea and vomiting (CINV)
Patients receiving chemotherapy via an infusion to transcatheter arterial chemoembolization were randomized to an active or placebo acupuncture group. Prior to chemotherapy, all patients received IV palonosetron. Patients received acupuncture 1–2 hours before chemotherapy, and more just after chemotherapy. Acupuncture was continued twice daily for six days. In the sham acupuncture group, electrodes were placed on the same acupoints for the same length of time and frequency, but no electrical stimulation was given. Severity and frequency of nausea and vomiting were recorded in patient diaries daily. P6, L14, and ST36 acupoints were used.
PHASE OF CARE: Active antitumor treatment
Double-blind, sham-controlled, randomized, controlled trial
No significant differences in CINV existed between groups. Anorexia was lower in the active acupuncture group from the second day onward (p < 0.0002).
Electroacupuncture was not shown to have an effect on CINV but appeared to have benefit for reducing anorexia.
Electroacupuncture was not effective in reducing CINV in this study but appeared to have a positive effect on appetite. Additional research is needed to determine any potential role of acupuncture for anorexia in patients with cancer.
Xiao, F., Song, X., Chen, Q., Dai, Y., Xu, R., Qiu, C., & Guo, Q. (2016). Effectiveness of psychological interventions on depression in patients after breast cancer surgery: A meta-analysis of randomized controlled trials. Clinical Breast Cancer. Advance online publication.
STUDY PURPOSE: To assess the effectiveness of Cognitive Behavioral Therapy (CBT) or CBT approach interventions for improving depressive symptoms
TYPE OF STUDY: Meta-analysis and systematic review
PHASE OF CARE: Not specified or not applicable
Analysis was conducted for each type of outcome measurement instrument used in the research. Across eight studies using the Self-Rating Depression Scale (SDS), the effect of the intervention was seen to be beneficial (standard mean difference [SMD] = –0.87, p < 0.0001). The pooled results of three studies for effects using the Hospital Anxiety and Depression Score (HADS) was also in favor of the intervention (SMD = –0.50, p = 0.04). Across all studies, the SMD comparing CBT to control was –0.92 (p < 0.00001).
Individually delivered CBT was shown to be effective in reducing the symptoms of depression among women with breast cancer.
In some studies, different cognitive behavioral approaches were used, and some delivered the intervention via a combination of face-to-face and telephonic contact. The results of the study quality evaluation were not reported. All studies excluded patients with major depression diagnoses.
Interventions using cognitive behavioral approaches can be effective to reduce the symptoms of depression in women having undergone surgery for breast cancer. Although full CBT is generally delivered by trained therapists, nurses can incorporate many of these principles into general patient teaching, counseling, and support. Patients with significant depression should be referred for appropriate management as needed.
Xiao, Y., Liu, J., Liu, Y.C., Huang, X.E., Guo, J.X., & Wei, W. (2014). Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Asian Pacific Journal of Cancer Prevention, 15, 3951–3954.
To evaluate the effects of an electronic antinausea instrument (EANI) combined with hydrochloride palonosetron versus hydrochloride palonosetron alone on nausea and vomiting during the administration of highly emetogenic chemotherapy
The treatment group received 0.25 mg of hydrochloride palonosetron injected five minutes before chemotherapy while wearing an EANI (no report of how long the patients wore the instrument). The control group received 0.25 mg of hydrochloride palonosetron injected five minutes before chemotherapy alone.
Randomized, controlled trial
There was a significant difference in the response rate for nausea (90% response in treatment group and 76.7% response in control group, p < 0.05), and there was a significant difference in the response rate for vomiting (95% response in treatment group and 78.3% response in control group, p < 0.05). No significant differences in adverse reactions between the groups and no severe adverse reactions were reported.
The use of an electronic antinausea instrument along with hydrochloride palonosetron appeared to be more effective than hydrochloride palonosetron alone for the treatment of acute nausea and vomiting associated with highly emetogenic chemotherapy.
Electronic antinausea instruments may be effective for treating chemotherapy-induced nausea and vomiting, but additional studies are needed to confirm these findings.
Xiao, Y., Liu, J., Huang, X. E., Ca, L.H., Ma, Y.M., Wei, W., . . . Wu, Y.J. (2014). Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pacific Journal of Cancer Prevention, 15, 10445–10449.
To assess the safety and efficacy of fluvoxamine combined with prolonged-release oxycodone for the management of cancer-related chronic pain
Patients with moderate to severe cancer-related pain were randomized to either the control group, which was treated with only prolonged-release oxycodone, or the prolonged-release oxycodone combined with fluvoxamine group. A daily maintenance dose of oxycodone was determined per patient after two weeks. Fluvoxamine began at 50 mg per day and increased by 50–100 mg per day to a maximum of 150 mg twice daily. Patients were assessed three times daily for pain response and dosage adjustment.
Randomized, open-label trial
Pain severity declined in both groups. There were no reported significant differences between groups for pain severity or opioid consumption.
The findings of this study did not demonstrate the efficacy of fluvoxamine for chronic pain management.
This study did not show any benefit from the addition of fluvoxamine to prolonged-release opioids in the management of moderate to severe chronic cancer-related pain.
Xiangyong, Y., Zhongsheng, Y., Wenchao, L., Hui, D., Shuzhou, Q., Gang, C., . . . Lian, Z. (2016). External application of traditional Chinese medicine in the treatment of bone cancer pain: A meta-analysis. Supportive Care in Cancer, 24, 11–17.
Applications: Palliative care
Analysis showed improved partial pain response with Chinese medicine compared to sustained release morphine or bisphosphonates (RR = 1.18, p = 0.02)
External application of traditional Chinese herbal medicine was shown here to improve pain response rate in patients with metastatic bone pain; however, the quality of the evidence is insufficient to draw firm conclusions
All studies were deemed to be of low quality. The authors noted that included studies were mainly from Chinese publications, and that it is known that negative results are not published in China. This suggests important publication bias.
There is currently insufficient good quality evidence to demonstrate efficacy of traditional Chinese herbal medicine for pain management. Findings of this meta analysis suggest promise for this type of intervention as adjunctive treatment; however, well-designed research is needed for evaluation of the evidence.
Wysocki, W.M., Mitus, J., Komorowski, A.L., & Karolewski, K. (2012). Impact of preoperative information on anxiety and disease-related knowledge in women undergoing mastectomy for breast cancer: A randomized clinical trial. Acta Chirurgica Belgica, 112, 111–115.
To evaluate the impact of information, provided preoperatively, on the anxiety and knowledge of women undergoing mastectomy for breast cancer; to assess the specific impact of additional, structured preoperative information (delivered by means of educational/informational video) on perioperative anxiety and treatment- and disease-related knowledge in women undergoing mastectomy for breast cancer
Routine information was delivered to both arms of the study. Information was not standardized and included the typical conversation with the attending surgeon, surgical informed consent, and practical information from nurses. The treatment arm provided additional information delivered preoperatively via video; the information was recorded by a breast cancer survivor. Information in the video was obtained from the National Cancer Institute’s website. All patients were prospectively followed for one month (further follow-up was performed according to local treatment protocols) at 24–36 hours, 7 days, and 30 days postoperatively.
Open-labeled, randomized controlled trial
Patients who participated in the study showed no evident or significant improvement in perioperative anxiety or treatment- and disease-related knowledge, with the exception of knowledge concerning available primary treatment modalities.
Patient education, as well as emotional support, should always be important preoperatively and must continue postoperatively.
Wyse, J.M., Carone, M., Paquin, S.C., Usatii, M., & Sahai, A.V. (2011). Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(26), 3541–3546.
To determine if early ultrasound-guided celiac plexus neurolysis (EUS-CPN) prevents pain progression in and reduces narcotic use by patients with painful inoperable pancreatic cancer
Eligible for the study were patients referred for endoscopic ultrasound for the diagnosis and staging of suspected pancreatic cancer with new onset of suspected cancer-related pain. If onsite cytopathology results confirmed the diagnosis of adenocarcinoma and the lesion was deemed inoperable, consenting patients were randomly assigned to EUS-CPN or no EUS-CPN. Celiac plexus neurolysis (CPN) was performed during the endoscopic procedure. After the procedure patients returned to the referring physician for ongoing pain management. One month after randomization, a patient could undergo open-label CPN at the physician’s discretion. Investigators assessed outcomes at one and three months after randomization.
Double-blind randomized controlled trial
Results show that, compared to pain management with narcotics alone, early EUS-CPN provides greater pain relief. In the sudied patients, this approach was not better than chemotherapy or radiation therapy for pain control.
For patients with painful inoperable pancreatic cancer, early EUS-CPN may provide better pain control than do opioids alone. However, this study does not show any difference in overall morphine consumption associated with EUS-CPN. In this group of patients, palliative chemotherapy or radiation therapy appears to achieve pain control similar to the pain control that EUS-CPN achieves. EUS-CPN has not been associated with early or late complications; it may produce fewer side effects and symptoms than chemotherapy or radiation therapy. For this group of patients, nurses can advocate for consideration of EUS-CPN for adjuvant pain management. The advantage of early EUS-CPN is that the procedure can be done at the same time as a staging procedure, limiting the number of invasive procedures that the patient has to undergo.
Wyatt, G., Sikorskii, A., Rahbar, M. H., Victorson, D., & You, M. (2012). Health-related quality-of-life outcomes: a reflexology trial with patients with advanced-stage breast cancer. Oncology Nursing Forum, 39, 568–577.
To evaluate the safety and efficacy of reflexology.
Patients were randomly assigned to one of three groups: reflexology, lay foot manipulation, or the control. Certified reflexology providers administered the reflexology intervention in four weekly, 30-minute sessions. Foot manipulation providers were laywomen trained in the procedure. The laywomen delivered foot manipulation according to the relexology schedule. The control group received standard care. Study data were collected at baseline and at 5 and 11 weeks after randomization. Reflexologists and foot manipulation providers collected data after sessions at the planned time points.
The study has clinical applicability for late effects and survivorship.
The study was a three-group, single-blind, randomized, controlled trial.
At baseline, scores regarding anxiety and depression, according to the Center for Epidemiologic Studies Depression Scale (CESD), differed significantly (p < 0.01) across study groups. No differences were found regarding quality of life and symptoms of depression, anxiety, pain, or nausea. Those receiving reflexology reported lower levels of dyspnea than did the other two groups (p ≤ 0.02). Patients getting foot manipulation from laywomen had lower fatigue scores than did the controls (p < 0.01). Further analysis showed that the effect on fatigue was mediated by changes in dyspnea. Eleven percent of those in the foot manipulation group and 10% of those in the reflexology group did not complete all the sessions. The intervention had no adverse effects.
The findings suggested that reflexology may improve the symptoms of dyspnea and that foot manipulation may help reduce fatigue in women with advanced-stage breast cancer. The authors noted no effect of reflexology or foot manipulation on pain, anxiety, symptoms of depression, or nausea.
The findings did not indicate that reflexology and foot manipulation affected pain, anxiety, symptoms of depression, or nausea among women with advanced breast cancer. The study demonstrated that these interventions are safe for the type of patients who participated. Reflexology and foot manipulation are low-risk interventions that may be helpful to some patients. Laypeople and caregivers could be taught these techniques, which may provide a meaningful way for these people to be involved in symptom management.
Wu, H., Dodd, M. J., & Cho, M. H. (2008). Patterns of fatigue and effect of exercise in patients receiving chemotherapy for breast cancer. Oncology Nursing Forum, 35, E90-E99.
To examine daily fatigue patterns during the third cycle of chemotherapy in women with breast cancer and predict whether fatigue trajectories differ by exercise or chemotherapy regimens.
Patients completed a daily fatigue diary that included a fatigue rating and items to determine whether they were exercisers or nonexercisers. Patients were asked to complete the diary daily. Weekly telephone calls from an exercise physiologist were used to determine exercise adherence. Adherence was determined as either a yes or no based on whether the patient exercised at least three days per week for 20 minutes per session and at a “somewhat hard” intensity. Measures obtained during the third course of chemotherapy were used in this analysis.
Patients were undergoing the active treatment phase of care.
This was a prospective, longitudinal, repeated-measure design primary study; a secondary analysis of these data was performed.
Average levels of fatigue reported were moderate for the first eight days and mild for the rest of the cycle. Highest levels of fatigue were observed on days 1 to 3 for average and worst fatigue. Five distinct trajectory patterns of cancer-related fatigue (CRF) were identified: immediate and sharp increase followed by a gradual decline; early peak, a decline, and a sharp increase toward the end of the cycle; small variations among daily scores; chaotic pattern; and step-up evaluation followed by a gradual decline. Nonexercisers had higher average and worst fatigue (p < 0.01). In exercisers and nonexercisers, fatigue declined in severity over time, and the rate of decline was not significantly different between the two groups; however, fatigue levels were consistently higher among nonexercisers.
CRF peaked in the days immediately after intravenous chemotherapy and declined gradually over time. Fatigue tended to be lower in those who exercised as described.
Nurses should provide anticipatory guidance to patients so that they can plan for the days when they are at most risk for fatigue. Continued exercise during the course of chemotherapy may be helpful in mitigating the severity of fatigue.